1-20 of 147 Search Results for

patent

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Article
J Health Polit Policy Law (2016) 41 (3): 423–450.
Published: 01 June 2016
... analysis health policy pharmaceutical patents In October 2015, the US government launched the Trans-Pacific Partnership, a trade agreement comprising twelve countries of the Pacific Rim, such as Chile and Peru, which among other economic liberalizations, enforce and expand intellectual property...
Journal Article
J Health Polit Policy Law (2013) 38 (4): 735–755.
Published: 01 August 2013
...Bhaven N. Sampat; Tahir Amin The 1995 Trade Related Intellectual Property Rights (TRIPS) agreement required developing countries to grant product patents in pharmaceuticals. Developing countries have since explored various measures to ameliorate potential negative effects of the new laws on public...
Journal Article
J Health Polit Policy Law (2022) 47 (6): 879–895.
Published: 01 December 2022
...Ameet Sarpatwari; Aaron S. Kesselheim; Robert Cook-Deegan Abstract More than 40 years have passed since the enactment of the Patent and Trademark Amendment (Bayh-Dole) Act, which authorized institutions to patent inventions arising from federally funded research. Although some experts have heralded...
Journal Article
J Health Polit Policy Law (2017) 42 (3): 485–512.
Published: 01 June 2017
...Cassandra M. Sweet Abstract When patents expire, are equivalent generic alternatives available to citizens? This article contributes to current discussion on access to medicine in the aftermath of the World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights...
FIGURES
Journal Article
J Health Polit Policy Law (2009) 34 (6): 979–1010.
Published: 01 December 2009
...Sandra Adamini; Hans Maarse; Esther Versluis; Donald W. Light After lengthening the duration of patents to twenty years in 1984, the pharmaceutical industry has turned to data exclusivity as a major vehicle for extending market protection, even after patents expire. Such protections give companies...
Journal Article
J Health Polit Policy Law (1994) 19 (3): 583–595.
Published: 01 June 1994
... of race in admitting patients. This practice is patently objectionable; it also is costly to hospitals, thus to society, since hospitals bear the direct costs of delayed discharges and hospitals do not keep costs to themselves. While research is needed to determine whether the North Carolina findings...
Journal Article
J Health Polit Policy Law (2016) 41 (2): 157–179.
Published: 01 April 2016
...Denis G. Arnold; Jennifer L. Troyer Abstract The pharmaceutical industry has been criticized for developing and aggressively marketing drugs that do not provide significant health benefits relative to existing drugs but retain the benefits of patent protection. Critics argue that drug marketing...
FIGURES
Journal Article
J Health Polit Policy Law (2024) 49 (1): 99–132.
Published: 01 February 2024
...) and the discussions on COVID-19 vaccine patent waivers at the World Trade Organization. Using the framework of “self-help” in the international system and country categorization to explicate country behaviors by state-business relations and expertise to explain South Korea's COVID-19 vaccine procurement process...
FIGURES | View All (4)
Journal Article
J Health Polit Policy Law (2023) 48 (2): 215–239.
Published: 01 April 2023
... of government-granted exclusivity: patents, which give their holders a 20-year exclusive right to make, use, sell, or import a covered invention; data or marketing exclusivities, which give companies residual control over the safety and efficacy data that they submit to regulators by blocking regulators from...
Journal Article
J Health Polit Policy Law (2013) 38 (4): 629–643.
Published: 01 August 2013
.... Quantitative approaches are also possible, however, as demonstrated by the article on public health safeguards in Indian patent law by the economist Bhaven Sampat and the attorney Tahir Amin. In recent years, public health law scholars and prac- titioners have focused attention on the potentially...
Journal Article
J Health Polit Policy Law (2014) 39 (3): 691–705.
Published: 01 June 2014
..., these recommendations address both goals. We start by examining pricing and procurement of patented medicines and then discuss both issues for generic medicines. Afterward, we offer an update of the current policy situation in Russia and conclude with proposals for the way forward. Retail prices...
FIGURES
Journal Article
J Health Polit Policy Law (2024) 49 (5): 911–938.
Published: 01 October 2024
..., but did not compete with, the EC's overarching policy choice to introduce patents on biotechnology. By contrast, the EP's proposal in the Biotechnology Directive to develop a Community strategy on R&D for diseases in the tropics (recital 2[a]) demanded an entirely different policy tool than the EC's...
FIGURES
Journal Article
J Health Polit Policy Law (2022) 47 (4): 523–526.
Published: 01 August 2022
...Joseph White Unfortunately, Feldman's story is not just of unethical businesses but of weak government. In many cases she describes instances where regulators (such as the US Patent and Trademark Office and the Federal Trade Commission) or the courts allowed behavior that, on the face...
Journal Article
J Health Polit Policy Law (2013) 38 (3): 573–597.
Published: 01 June 2013
...) . Cambridge, MA : National Bureau of Economic Research . Ching A. T. 2010 . “A Dynamic Oligopoly Structural Model for the Prescription Drug Market after Patent Expiration.” International Economic Review 51 , no. 4 : 1175 – 207 . Cohen M. R. Di Domizio G. Lee R. E. Jr...
Journal Article
J Health Polit Policy Law (2024) 49 (1): 43–72.
Published: 01 February 2024
... and patented technologies. For instance, COVID-19 vaccines incorporate a large number of technologies, ranging from the modified adenoviral vectors to the lipid nanoparticles used to deliver mRNA and spike proteins that serve as the critical antigens (Asundi, O'Leary, and Bhadelia 2021 ). The ability...
Journal Article
J Health Polit Policy Law (2013) 38 (4): 879–885.
Published: 01 August 2013
... a practicing solicitor in the Senior Courts of England and Wales for more than ten years, and adviser to various organizations including the World Health Organization, UNITAID, and GAVI Alliance. He has written extensively on pharmaceutical patenting and published articles in Health Affairs, Science...
Journal Article
J Health Polit Policy Law (2007) 32 (5): 895–913.
Published: 01 October 2007
... to entire corporate com- puter or software systems or legal expenses pertinent to R&D, patents, and new products (Light 2006a). Third, no mention was made by the authors of verifying the data or cleaning it in the usual ways done by researchers using open-source data sets. Fourth, there may have been...
Image
Published: 01 October 2019
in 2015, both Viagra and Cialis started to prepare for the end of their patents with reduced advertising budgets. More
Journal Article
J Health Polit Policy Law (2011) 36 (5): 905–908.
Published: 01 October 2011
... and School of International and Public Affairs. An economist by training, Sampat is centrally interested in issues at the intersection of health policy and innovation policy. His current work examines generic challenges to pharmaceutical patents in the United States, the effects of new patent laws...
Journal Article
J Health Polit Policy Law (2003) 28 (4): 615–658.
Published: 01 August 2003
... . European Policies Influencing Pharmaceutical Innovation. In The Changing Economics of Medical Technology , ed. Institute of Medicine. Washington, DC: National Academy Press. Campbell, R. M., and L. A. Pal. 1989 . The Long and Winding Road: Bill C-22 and the Politics of Drug Patents. In The Real...